Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma

Journal of Orthopaedic Research

Volumn 28, Issue 12, 2010, Pages 1621-1625

  Xu, Jianda ^a   Wu, Sujia ^a   Shi, Xin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

osteosarcoma; prognosis; RECK; survival

Indexed keywords

MATRIX METALLOPROTEINASE; MEMBRANE PROTEIN; RECK PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; DISEASE ASSOCIATION; ENZYME REGULATION; FEMALE; GENE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; OSTEOSARCOMA; PREDICTOR VARIABLE; PRESCHOOL CHILD; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIF GENE; SURVIVAL RATE; ADOLESCENT; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MATRIX METALLOPROTEINASES; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; OSTEOSARCOMA; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 78149476388     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21178     Document Type: Article

References (25)

1. Bielack SS, Kempf-Bielack B, Delling G, et al. 2002. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An Analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20: 776 -790.
2. Link MP, Goorin AM, Miser AW, et al. 1986. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314: 1600 -1606.
3. Wunder JS, Nielsen TO, Maki RG, et al. 2007. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 8: 513 -524.
4. Takahashi C, Sheng Z, Horan TP, et al. 1998. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane anchored glycoprotein RECK. Proc Natl Acad Sci USA 95: 13221 -13226.
5. Oh J, Takahashi R, Kondo S, et al. 2001. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107: 789 -800.
6. Masui T, Doi R, Koshiba T, et al. 2008. RECK expression in pancreatic cancer: Its correlation with lower invasiveness and better prognosis. Clin Cancer Res 9: 1779 -178
7. Furumoto K, Arii S, Mori A, et al. 2001. RECK gene expression in hepatocellular carcinoma: Correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing-cysteine-rich protein with Kazal motifs. Hepatology 33: 189 -195.
8. Span PN, Sweep CG, Manders P, et al. 2003. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: A prognostic marker for good clinical outcome in human breast carcinoma. Cancer 97: 2710 -2715.
9. Takenaka K, Ishikawa S, Kawano Y, et al. 2004. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer [J]. Eur J Cancer 40: 1617 -1623.
10. Taku T, Michiyoshi H, Mitsuo N, et al. 2004. The membrane-anchored matrix metalloproteinase regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res 10: 5572 -5579.
11. Rosen G,. 1985. Preoperative (neoadjuvant) chemo-therapy for osteogenic sarcoma: A ten years experience. Orthopedics 8: 659 -664.
12. Enneking WF,. 1986. A system of staging musculoskeletal neoplasms. Clin Orthop 204: 9 -24.
13. Huvos AG, Rosen G, Marcove RC,. 1977. Primary osteogenic sarcoma: Pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 101: 14 -18.
14. Takenaka K, Ishikawa S, Yanagihara K, et al. 2005. Prognostic significance of reversion-inducing cysteine-rich protein with Kazal Motifs Expression in resected pathologic stage IIIAN2 non-small-cell lung cancer. Ann Surg Oncol 12: 817 -824.
15. Kim MS, Song WS, Cho WH, et al. 2007. Ezrin expression predicts survival in stage IIB osteosarcomas. Clin Orthop Relat Res 459: 229 -236.
16. Baldini N, Scotlandi K, Barbanti-Bròdano G, et al. 1995. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333: 1380 -1385.
17. Laverdiere C, Hoang BH, Yang R, et al. 2005. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 11: 2561 -2567.
18. Dass CR, Nadesapillai AP, Robin D, et al. 2005. Downregulation of uPAR conWrms link in growth and metastasis of osteosarcoma. Clin Exp Metastasis 22: 643 -652.
19. Osaka E, Suzuki T, Osaka S, et al. 2006. Survivin as a prognostic factor for osteosarcoma patients. Acta Histochem Cytochem 39: 95 -100.
20. Tomohiro A, Takuro W, Yasuo K,. 2002. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 94: 1397 -1404.
21. Kang HG, Kim HS, Kim KJ, et al. 2007. RECK expression in osteosarcoma: Correlation with matrix metalloproteinases activation and tumor invasiveness. J Orthop Res 25: 696 -702.
22. Woodhouse EC, Chuaqui RF, Liotta LA,. 1997. General mechanisms of metastasis. Cancer 80: 1529 -1537.
23. Oh J, Takahashi R, Kondo S, et al. 2001. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107: 789 -800.
24. Meng N, Li Y, Zhang H, Sun XF,. 2008. RECK a novel matrix metalloproteinase regulator. Histol Histopathol 23: 1003 -1010.
25. Rhee JS, Coussens LM,. 2002. Recking MMP function: Implications for cancer development. Trends Cell Biol 12: 209 -211.